Catalent and GelMEDIX Enter Global Partnership for the Development and Clinical Manufacturing of iPSC-Derived Cell Therapies in Ocular and Retinal Diseases

TAMPA, Fla. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Catalent and GelMEDIX Enter Global Partnership for manufacturing and development of iPSC-Derived Cell Therapies in Ocular and Retinal Diseases.